Peter Condon work email
- Valid
- Valid
- Valid
- Valid
- Valid
Peter Condon personal email
Peter Condon phone numbers
Strategic and results-oriented senior executive with 20+ years of experience in the biotechnology industry, seeking to contribute business development, commercial strategy, and operational expertise as a Chief Business Officer. Versatile and collaborative leader with a strong track record of defining business development and commercial strategies and executing high-value transactions to optimize product portfolios. Recognized for mentoring and leading high-performance teams, building R&D infrastructure for startup biotech companies, and for broad network of key decision-makers at large pharma. • Portfolio Optimization• Corporate Development Strategy• Operational Excellence• Commercial PlanningPortfolio OptimizationCompleted 20+ global acquisitions/licensing agreements representing billions of dollars in asset value to build product pipelines. Collaborated with C-suite executives to prioritize therapeutic programs for out-licensing. Corporate Development StrategyCollaborated with C-suite executives and Board of Directors to define and lead corporate development strategy and goals. Developed key research, development, and commercial criteria for acquisitions/in-licenses and divestitures that focused and strategically aligned business development activities. Operational ExcellenceDefined and implemented business development process improvements to streamline and augment all aspects of sourcing, diligence, and deal negotiations. Improved deal timelines by 30% and eliminated diligence oversights. Led initiatives to build start-up biotech research infrastructure, including executing leases and other agreements for research facilities. Commercial PlanningLed all aspects of commercial planning for pipeline therapeutics, including market research, competitive analyses, product pricing, positioning and segmentation, revenue forecasts, and lifecycle planning. Efforts contributed to the launch of the first biologic for asthma that achieved $2B+ in sales.
Dtx Pharma
-
Chief Business OfficerDtx Pharma Jun 2022 - Present
-
Independent ConsultantCondon Lifesci Consulting Aug 2021 - Aug 2022Focused on biotech companies in strategy, business development, capital raising and operations. • Acting COO for a stealth mode, pre-Series A company developing gene therapies for rare diseases. Responsibilities include corporate strategy to focus on developing drug candidates for highest value indications, building operational plans and budgets, developing investor pitch decks and co-leading $60M Series A capital raise.• Acting CBO for Aristea Therapeutics – a private biotech company focused on developing therapies for autoimmune disease. Identifying and evaluating external therapeutic opportunities to entirely rebuild the company’s pipeline in the next 12 month. Lead negotiations with potential partners. • Collaborating with executive team of publicly traded biotech company developing autoimmune disease therapies to define sell-side partnering strategy. Refining the corporate pitch decks and leading outreach to potential partners.
-
Vice President & Head Of Business Development And Alliance ManagementGossamer Bio 2018 - Jul 2021San Diego, California, UsProvided strategic direction and leadership for global business development and alliance management. Drove therapeutic pipeline expansion and optimization, including defining the BD buy-and-sell-side strategy. Represented the company at partnering meetings. Sourced potential collaboration partners, led due diligence teams, negotiated license and acquisition agreements, gained board approval, and managed collaborations after deal completion. • Created the BD strategy by working with C-suite executives to define gaps in the pipeline, prioritize diseases and biological pathways, and specify the critical criteria to identify highest-value opportunities. Efforts resulted in a more efficient process and a 30% reduction in deal timelines.• Closed 9 agreements that doubled the preclinical pipeline. -
Executive Director, Business DevelopmentCalico Life Sciences 2015 - 2018South San Francisco, Ca, UsExpanded research infrastructure and identified external therapeutic opportunities, led due diligence and deal negotiations, and presented to CEO updates on progress towards closing transactions. • Closed 5 therapeutic licensing and collaboration agreements with biotech and academic partners, including the C4 Therapeutics protein degrader discovery collaboration. Transactions amounted to 50% of the company’s pipeline.• Built Calico’s research operations, including closing multiple transactions governing construction and lease of external research facilities. -
Executive Director, Business DevelopmentAlexion Pharmaceuticals 2010 - 2014Boston, Massachusetts, UsManaged global team that identified external therapeutic programs, led due diligence, negotiated deal terms, and presented opportunities to CEO for approval. • Co-led the $1B acquisition of Enobia Pharmaceuticals, a private company with a Phase II therapy for hypophosphatasia, an ultra-rare bone disease. Drug approved worldwide and achieved $700M in WW annual sales. • Closed 7 transactions in total that augmented the product pipeline and accounted for 75% of the company’s portfolio. -
Associate Director, Business Development - OncologyGenentech 2003 - 2010South San Francisco, California, UsIdentified therapeutic licensing opportunities, led diligence teams, negotiated deal terms, and presented deal opportunities for approval to senior management. • Completed 13 transactions, including a $310M small molecule oncology R&D collaboration with Nerviano Medical Sciences and a licensing agreement with Arius Research to develop a preclinical anti-CD63 antibody program. -
Group Market Planning Manager, Genentech Market DevelopmentGenentech 2000 - 2003South San Francisco, California, UsDeveloped marketing strategies for Xolair and other pipeline products. Responsibilities included competitive analyses, product pricing, positioning and segmentation, revenue forecasts, and lifecycle planning. Assessed commercial value of immunology licensing opportunities for Business Development.
-
Associate - Financial And Health ServicesBooz Allen Hamilton 1998 - 1999Mclean, Va, UsIdentified and prioritized strategies to enhance profitability and growth for prominent health care companies. -
ConsultantAdvisory Board 1994 - 1996Washington, District Of Columbia, UsPrepared best-practice management and marketing studies for physician and hospital networks.
Peter Condon Skills
Peter Condon Education Details
-
Harvard UniversityEconomics -
The Wharton SchoolMaster Of Business Administration - Mba
Frequently Asked Questions about Peter Condon
What company does Peter Condon work for?
Peter Condon works for Dtx Pharma
What is Peter Condon's role at the current company?
Peter Condon's current role is Biosciences Executive | Business Development | Commercial Strategy | Operations Leadership.
What is Peter Condon's email address?
Peter Condon's email address is co****@****lxn.com
What is Peter Condon's direct phone number?
Peter Condon's direct phone number is 941-556*****
What schools did Peter Condon attend?
Peter Condon attended Harvard University, The Wharton School.
What skills is Peter Condon known for?
Peter Condon has skills like Pharmaceutical Industry, Biotechnology, Life Sciences, Business Development, Biopharmaceuticals, Technology Transfer, Drug Development, Clinical Development, Oncology, Drug Discovery, Licensing, Due Diligence.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial